Eric Nou1, Norra Kwong, Lukas K Alexander, Edmund S Cibas, Ellen Marqusee, Erik K Alexander. 1. Thyroid Section (E.N., N.K., L.K.A., E.M., E.K.A.), Division of Endocrinology, Hypertension, and Diabetes, Department of Medicine, and the Department of Pathology (E.S.C.), The Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115.
Abstract
INTRODUCTION: The optimal timing for repeat evaluation of a cytologically benign thyroid nodule greater than 1 cm is uncertain. Arguably, the most important determinant is the disease-specific mortality resulting from an undetected thyroid cancer. Presently there exist no data that evaluate this important end point. METHODS: We studied the long-term status of all patients evaluated in our thyroid nodule clinic between 1995 and 2003 with initially benign fine-needle aspiration (FNA) cytology. The follow-up interval was defined from the time of the initial benign FNA to any one of the following factors: thyroidectomy, death, or the most recent clinic visit documented anywhere in our health care system. We sought to determine the optimal timing for repeat assessment based on the identification of falsely benign malignancy and, most important, disease-related mortality due to a missed diagnosis. RESULTS: One thousand three hundred sixty-nine patients with 2010 cytologically benign nodules were followed up for an average of 8.5 years (range 0.25-18 y). Thirty deaths were documented, although zero were attributed to thyroid cancer. Eighteen false-negative thyroid malignancies were identified and removed at a mean 4.5 years (range 0.3-10 y) after the initial benign aspiration. None had distant metastasis, and all are alive presently at an average of 11 years after the initial falsely benign FNA. Separate analysis demonstrates that patients with initially benign nodules who subsequently sought thyroidectomy for compressive symptoms did so an average of 4.5 years later. CONCLUSIONS: An initially benign FNA confers negligable mortality risk during long-term follow-up despite a low risk of identifying several such nodules as thyroid cancer. Because such malignancies appear adequately treated despite detection at a mean 4.5 years after falsely benign cytology, these data support a recommendation for repeat thyroid nodule evaluation 2-4 years after the initial benign FNA.
INTRODUCTION: The optimal timing for repeat evaluation of a cytologically benign thyroid nodule greater than 1 cm is uncertain. Arguably, the most important determinant is the disease-specific mortality resulting from an undetected thyroid cancer. Presently there exist no data that evaluate this important end point. METHODS: We studied the long-term status of all patients evaluated in our thyroid nodule clinic between 1995 and 2003 with initially benign fine-needle aspiration (FNA) cytology. The follow-up interval was defined from the time of the initial benign FNA to any one of the following factors: thyroidectomy, death, or the most recent clinic visit documented anywhere in our health care system. We sought to determine the optimal timing for repeat assessment based on the identification of falsely benign malignancy and, most important, disease-related mortality due to a missed diagnosis. RESULTS: One thousand three hundred sixty-nine patients with 2010 cytologically benign nodules were followed up for an average of 8.5 years (range 0.25-18 y). Thirty deaths were documented, although zero were attributed to thyroid cancer. Eighteen false-negative thyroid malignancies were identified and removed at a mean 4.5 years (range 0.3-10 y) after the initial benign aspiration. None had distant metastasis, and all are alive presently at an average of 11 years after the initial falsely benign FNA. Separate analysis demonstrates that patients with initially benign nodules who subsequently sought thyroidectomy for compressive symptoms did so an average of 4.5 years later. CONCLUSIONS: An initially benign FNA confers negligable mortality risk during long-term follow-up despite a low risk of identifying several such nodules as thyroid cancer. Because such malignancies appear adequately treated despite detection at a mean 4.5 years after falsely benign cytology, these data support a recommendation for repeat thyroid nodule evaluation 2-4 years after the initial benign FNA.
Authors: Mary C Frates; Carol B Benson; Peter M Doubilet; Elizabeth Kunreuther; Maricela Contreras; Edmund S Cibas; Joseph Orcutt; Francis D Moore; P Reed Larsen; Ellen Marqusee; Erik K Alexander Journal: J Clin Endocrinol Metab Date: 2006-07-11 Impact factor: 5.958
Authors: Erik K Alexander; Shelley Hurwitz; Jenny P Heering; Carol B Benson; Mary C Frates; Peter M Doubilet; Edmund S Cibas; P Reed Larsen; Ellen Marqusee Journal: Ann Intern Med Date: 2003-02-18 Impact factor: 25.391
Authors: Leila Yassa; Edmund S Cibas; Carol B Benson; Mary C Frates; Peter M Doubilet; Atul A Gawande; Francis D Moore; Brian W Kim; Vânia Nosé; Ellen Marqusee; P Reed Larsen; Erik K Alexander Journal: Cancer Date: 2007-12-25 Impact factor: 6.860
Authors: Kelly L McCoy; Noel Jabbour; Jennifer B Ogilvie; N Paul Ohori; Sally E Carty; John H Yim Journal: Surgery Date: 2007-11-05 Impact factor: 3.982
Authors: Kepal N Patel; Trevor E Angell; Joshua Babiarz; Neil M Barth; Thomas Blevins; Quan-Yang Duh; Ronald A Ghossein; R Mack Harrell; Jing Huang; Giulia C Kennedy; Su Yeon Kim; Richard T Kloos; Virginia A LiVolsi; Gregory W Randolph; Peter M Sadow; Michael H Shanik; Julie A Sosa; S Thomas Traweek; P Sean Walsh; Duncan Whitney; Michael W Yeh; Paul W Ladenson Journal: JAMA Surg Date: 2018-09-01 Impact factor: 14.766
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: Su Min Ha; Jung Hwan Baek; Young Jun Choi; Sae Rom Chung; Tae Yon Sung; Tae Yong Kim; Jeong Hyun Lee Journal: Eur Radiol Date: 2018-06-19 Impact factor: 5.315
Authors: Trevor E Angell; Mary C Frates; Marco Medici; Xiaoyun Liu; Norra Kwong; Edmund S Cibas; Matthew I Kim; Ellen Marqusee Journal: J Clin Endocrinol Metab Date: 2015-09-09 Impact factor: 5.958
Authors: Samantha Ly; Mary C Frates; Carol B Benson; Hope E Peters; Frederick D Grant; Laura A Drubach; Stephan D Voss; Henry A Feldman; Jessica R Smith; Justine Barletta; Monica Hollowell; Edmund S Cibas; Francis D Moore; Biren Modi; Robert C Shamberger; Stephen A Huang Journal: J Clin Endocrinol Metab Date: 2016-08-08 Impact factor: 5.958